Camrelizumab vs Toripalimab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline

Camrelizumab

Marketed by Jiangsu Hengrui Pharmaceuticals and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Partial signal

NCT03134872 · Phase 3 · completed

CameL was a randomized, open-label Phase 3 trial in 419 patients with untreated non-squamous non-small-cell lung cancer without EGFR or ALK alterations, which compared camrelizumab plus carboplatin and pemetrexed with chemotherapy alone. It had two primary endpoints: progression-free survival in all patients and in PD-L1-positive patients. At the interim analysis, progression-free survival in all patients was significantly longer with camrelizumab (11.3 vs 8.3 months; hazard ratio 0.60). The paper reports confirmatory testing only for all patients, and no published result tests the PD-L1-positive primary, so the result is shown as unclear. The figures come from the peer-reviewed paper (Zhou et al., Lancet Respir Med 2021).

Next expected readout: December 2027 · NCT07016126 (registry estimate)

Reported efficacy

Progression-Free Survival in the intent-to-treat (ITT) population (up to 24 months); Progression-Free Survival in the PD-L1-selected population (up to 24 months): Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported. (unclear)

Result source: NCT03134872

Toripalimab

Marketed by Coherus BioSciences, Inc. and partners

Phase 3 in Non-Small Cell Lung Cancermonoclonal antibody
Reliable signal

NCT03856411 · Phase 3 · completed

This randomized, quadruple-blind, placebo-controlled trial of 465 patients met its primary endpoint: median progression-free survival was 8.4 months with toripalimab plus chemotherapy versus 5.6 months with placebo plus chemotherapy, a highly statistically significant improvement.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: December 2026 · NCT06426511 (registry estimate)

Reported efficacy

MPR rate in stage III population evaluated by BIPR (up to 7 weeks after neoadjuvant); EFS in stage III population evaluated by investigators (up to 3 years); MPR rate in stage II-III population evaluated by BIPR (up to 7 weeks after neoadjuvant); EFS in stage II-III population evaluated by investigators (up to 3 years): Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met. (met)

Result source: NCT04158440

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointCamrelizumabToripalimab
PFS, median11.3 vs 8.3avs carboplatin + pemetrexed alone, PCNCT031348728.4 vs 5.6a+2.8 vs placeboNCT03856411
OS, median—Not posted · NCT03134872—Not posted · NCT03856411
ORR16.7%b375 mg · n 12NCT03083041—Not posted · NCT03856411
Duration of response, median—Not posted · NCT03134872—Not posted · NCT03856411

PFS, median

Camrelizumab
11.3 vs 8.3avs carboplatin + pemetrexed alone, PCNCT03134872
Toripalimab
8.4 vs 5.6a+2.8 vs placeboNCT03856411

OS, median

Camrelizumab
—Not posted · NCT03134872
Toripalimab
—Not posted · NCT03856411

ORR

Camrelizumab
16.7%b375 mg · n 12NCT03083041
Toripalimab
—Not posted · NCT03856411

Duration of response, median

Camrelizumab
—Not posted · NCT03134872
Toripalimab
—Not posted · NCT03856411
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  3. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  4. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Camrelizumab: 3 of 4 rows · Toripalimab: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricCamrelizumabToripalimab
Dropout rate
91.7%375 mga
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
—250 mg
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
—
Discontinued due to AEs
—375 mga
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
—250 mg
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
—
Serious AEs
58.3%375 mga
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
56.6%250 mg
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
—
Most frequent reported AEs
375 mga
rash 91.7%
hypertension 83.3%
decreased appetite 75%
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
250 mg
hypertension 63.6%
proteinuria 63.1%
aspartate aminotransferase increased 53.5%
NCT03083041 · Phase 2 · registry result, not featured evidence · combination
—

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Camrelizumab

ORR 16.7% (n=12)375 mg
responder rate · % of participants
No placebo or comparator arm
NCT03083041 · Phase 2 · registry result, not featured evidence · combination

Nasopharyngeal Carcinoma

Shared mechanism: PD-1 · full Nasopharyngeal Carcinoma pipeline

Camrelizumab

Marketed by Jiangsu Hengrui Pharmaceuticals and partners

Phase 3 in Nasopharyngeal Carcinomamonoclonal antibody
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: November 2027 · NCT06669611 (registry estimate)

No aligned efficacy figure on record for this race.

Toripalimab

Marketed by Coherus BioSciences, Inc. and partners

Approved in Nasopharyngeal Carcinomamonoclonal antibody
Partial signal

NCT03581786 · Phase 3 · completed

JUPITER-02 was a randomized, double-blind, placebo-controlled Phase 3 in 289 patients with recurrent or metastatic nasopharyngeal carcinoma. Its primary endpoint, independently reviewed progression-free survival, is a clinical outcome and was met (HR 0.52). Figures are from the FDA label; the sources read give no power calculation, so the grade is moderate.

Next expected readout: December 2026 · NCT06323239 (registry estimate)

Reported efficacy

IRC-assessed Progression-Free Survival (PFS) According to RECIST v1.1 (up to 2 years): Primary endpoint, IRC-assessed PFS: median 11.7 vs 8.0 months, hazard ratio 0.52 (95% CI 0.36 to 0.74), toripalimab plus gemcitabine-cisplatin vs placebo plus gemcitabine-cisplatin (LOQTORZI label, JUPITER-02). (met)

Result source: NCT03581786

Results for Nasopharyngeal Carcinoma

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Camrelizumab: no structured comparison results are available for Nasopharyngeal Carcinoma.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Toripalimab
Primary endpoint, IRC-assessed PFS: median 11.7 vs 8.0 months, hazard ratio 0.52 (95% CI 0.36 to 0.74), toripalimab plus gemcitabine-cisplatin vs placebo plus gemcitabine-cisplatin (LOQTORZI label, JUPITER-02). NCT03581786 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Camrelizumab's landscape · Toripalimab's landscape